midesteine
a cyclic thiolic neutrophil elastase inhibitor
Also Known As:
(2-(3-thiophencarboxythio)-N-(dihydro-2(3H)-thiophenone-3-I))propionamide; MR 889; MR-889; MR889; N-(S-(2-thiophenecarbonyl)-2-mercaptopropionyl)homocysteine lactone; 2-Thiophenecarbothioic acid, S-(1-methyl-2-oxo-2-((tetrahydro-2-oxo-3-thienyl)amino)ethyl) ester
Networked: 4
relevant articles (1 outcomes,
1 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
Related Diseases
1. | Chronic Obstructive Pulmonary Disease (COPD)
07/01/1996
- " We conclude that MR889 is safe to administer to COPD patients for a period of at least 4 weeks. " 07/01/1996
- " Nevertheless, a subset of treated patients with fairly short disease duration showed a post-treatment reduction of desmosine urine levels, thus justifying the need for further studies to prove the efficacy of MR889 in modulating indices of lung destruction in COPD." 07/01/1996
- " During this time, MR889 does not modify biochemical markers of lung destruction in unselected COPD patients. " 07/01/1996
- " We investigated whether MR889, a synthetic cyclic thiolic elastase inhibitor, administered for a period of 4 weeks to chronic obstructive pulmonary disease (COPD) patients, is well-tolerated, and whether it modifies biochemical indices of lung destruction. " 07/01/1996
- " MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial."
|
2. | Chronic Bronchitis
|
|
Related Drugs and Biologics
Related Therapies and Procedures